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The present study shows low circulating levels of SIRT4 in obese patients with nonalcoholic fatty liver disease mirroring its reduced
mitochondrial expression in an attempt to increase the fat oxidative capacity and then the mitochondrial function in liver and in
muscle. SIRT4 modulates the metabolism of free fatty acids reducing their high circulating levels but, unfortunately, increasing
ROS production. Great concentration of free fatty acids, released by adipose tissue, coupled with oxidative stress, directly results in
endothelial dysfunction, early atherosclerosis, and coronary artery disease risk factor.
1. Introduction
Both obesity and themetabolic syndrome (MS) in developing
countries lead to increased mortality closely associated with
coronary artery disease (CAD). The molecular mechanism
of obesity involves downregulation of genes not only in
free fatty acid (FFA) oxidation [1] but also in muscle [2].
Sirtuin (SIRT) 4 is an ADP-ribosyltransferase of 59 kDa
variably expressed in liver mitochondria and in skeletal
muscle and is associated with homeostasis of glucose/lipid
metabolism. In particular, experimental studies using SIRT4
expression in primary hepatocytes and myotubes have evi-
denced its role as negative regulator of the mitochondrial
oxidative metabolism. Accordingly, SIRT4 knockdown leads
to increased FFA oxidation in liver and in muscle [2]. On
the other hand, SIRT4 decreases the amino acid-stimulated
insulin secretion by inhibiting the glutamate dehydrogenase
activity in pancreatic 𝛽-cells [3, 4]. Furthermore, SIRT4
expression is reduced in the rat model of insulin resistance
[5] and low SIRT4mRNA expression was found in peripheral
blood leukocytes in human type 2 diabetes mellitus [6].
Unclassified nonalcoholic fatty liver disease (NAFLD)
or hepatic steatosis (nonalcoholic HS), characterized by
excess triglyceride (TG) storage in the liver, is a further
expression of the MS [7] and is an independent predictor
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of CAD risk [8]. Obese people have increased intramuscular
TG (IMTG) accumulation [9]. This fat deposition, due to
altered production of mitochondrial ATP, is linked to IR [10].
Intramuscular fat increases the muscle echo intensity and
can easily be evaluated by ultrasound [11]. Common carotid
intima-media thickness (cIMT) is a functional and structural
marker of the atherosclerotic process [12]. The results of a
recent study highlight the negative correlation of myocardial
triacylglycerol accumulation with calorimetric changes, that
is, resting metabolic rate (RMR), as a novel biomarker of
CAD risk, in the sense that reduced energy expenditure
and oxygen consumption may provide novel risk factors of
obesity-induced reduced energy generation for myocardial
contractile function [13].
We aimed at investigating in a sample of obese indi-
viduals whether circulating levels of SIRT4 were correlated
with anthropometric measures, metabolic and calorimetric
profile, HS, low-grade chronic inflammation markers, and
strict CAD risk factors, such as IMT.
2. Methods
2.1. Population. This research was performed by screening
234 consecutive subjects referred to the out-patientMetabolic
Unit, from June 2010 to September 2012, for established obe-
sity (at least three years), who were on a balanced low calorie,
low fat (25% of calories) diet (lasting at least three months)
and were characterized by sedentary life style. This cross-
sectional study was carried out according to the principles of
theDeclaration ofHelsinki and informedwritten consentwas
obtained from each patient.
2.2. Enrollment Criteria. Of the initial 234 participants, 18
were excluded due to marked intestinal meteorism which
made it difficult to perform abdominal ultrasound (first
step to screening HS), 17 patients due to steroid therapy
(eight for bronchial asthma, five for rheumatoid arthritis,
two for neuritis, and two for inflammatory bowel disease),
and 32 due to taking one or more drugs (i.e., aspirin,
metformin, statins, and fibrates) known to possibly alter
laboratory data. Sixteen others were excluded because they
presented hepatic comorbidities in their medical history
(HCV/HBV infection, alcohol abuse, and PBC); finally eleven
subjects were considered drop-outs because they refused
to undergo full laboratory-instrumental examinations. Of
the 140 patients who formed the final study population,
characterized by obesity and presence of HS, with normal or
slight increase of liver enzymes, and for the most part also
by IMTG, ten morbidly obese patients underwent bariatric
surgery during which a liver biopsy was obtained. Twenty
lean, apparently healthy, subjects (screened for the entire
laboratory panel and instrumental parameters used for the
obese individuals) were chosen as controls to set reference
value of circulating SIRT4. Further criteria for diagnos-
ing HS were any viral, autoimmune, and metabolic liver
disease (Wilson disease, hemochromatosis, or antitrypsin
deficiency), ruled out by appropriate testing, following the
generally accepted diagnostic guidelines. Celiac disease was
excluded by estimates of IgA antitissue transglutaminase
antibodies. Alcohol abuse was ruled out, according to the
DSM-IV diagnostic criteria, by means of screening tests
such as Michigan Alcohol Screening Test (MAST) and Cut
down, Annoyed, Guilty, and Eye opener (CAGE), as well as
random tests for blood alcohol concentration and the use of
a surrogate marker, for example, mean corpuscular volume.
Patients on antihypertensive drugs maintained a balanced
therapeutic regimen throughout the study.
2.3. Anthropometrics andMetabolic Profile. The three degrees
of obesity (light, moderate, and severe) were established on
the basis of BMI cut-off points of 30–34.9 and 35–39.9 and
>40 kg/m2, respectively. MS was not categorized but every
criterion was analyzed. Visceral obesity was identified by
measuring WC at the midpoint between the lower border
of the rib cage and the iliac crest. Hip circumference was
measured around the widest part of the buttocks, with the
tape parallel to the floor, and the waist-to-hip (W/H) ratio
was calculated. IR status was determined by the homeo-
static metabolic assessment (HOMA), which was assessed
by the formula: fasting insulin (𝜇U/mL) × fasting glucose
(mg/dL)/405. Moreover, as the repeated HOMA measure-
ments presented high within person variability in obese
patients, HOMA values were averaged on the basis of at least
five determinations to avoid misclassification.
2.4. Indirect Calorimetry. RMR was measured by indirect
calorimetry using a canopy system (V max 29 N, Sensor
Medics, Anaheim, USA) in a quiet environment and with
patients in the supine position for 30min before measure-
ment. After a 15–20min adaptation to the instrument, oxygen
consumption and carbon dioxide production were deter-
mined for 45min. Energy expenditure was derived fromCO
2
production and O
2
consumption with the appropriate Weir
formula neglecting protein oxidation [14]. BMR, expressed
as kcal/24 h, was adjusted for changes in fat-free mass (FFM),
which was evaluated by single-frequency bioimpedance anal-
ysis obtaining aRMR/FFMratio, expressed as kcal/24 h∗kg of
body [15].
2.5. Ultrasound Evaluation. Ultrasonographicmeasurements
were performed using an Esaote system (Genoa, Italy).
Specifically, transverse scanning was performed to measure
the subcutaneous adipose tissue (SAT) and visceral adipose
tissue (VAT) using an eleven and 3.5MHz linear probe convex
probe, respectively. The SAT was defined as the thickness
between the skin-fat interface and the linea alba, avoiding
compression. The VAT was defined as the distance between
the anterior wall of the aorta and the internal face of the
rectoabdominalmuscle perpendicular to the aorta, measured
one cm above the umbilicus. When the aortic walls were
not visualized as they were obscured by bowel gas, the
Doppler scan was used. Spleen longitudinal diameter (SLD)
as index of low-grade chronic inflammation [16] was chosen
to evaluate spleen volume and was carried out by postero-
lateral scanning. Maximum length (the optically greatest
overall longitudinal dimension obtained from one of the
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Figure 1: Skeletal muscle image. Echo intensity at ultrasound of a normal muscle (grade I) with related anatomic structures.
two poles) and craniocaudal length (the optically maximal
transversal dimension intercepting one of the two poles) were
measured; the resulting values were then averaged, since the
two measurements do not always coincide. The classification
of “bright liver” or HS was based on the following scale of
hyperechogenicity: grade 0 = absent, grade 1 = light, grade 2 =
moderate, and grade 3 = severe, pointing out the difference
between the densities of the liver and the right kidney [17].
Technically, echo intensity can be influenced bymany factors,
particularly by gain intensity. To avoid confounding factors
that could modify echo intensity and thus bias comparisons,
mean brightness levels of both liver and right kidney cortex
were obtained on the same longitudinal sonographic plane.
Muscle ultrasound, performed at the level of the biceps
muscle of the left superior arm, is a convenient technique
to visualize pathological muscle tissue, as it is noninvasive
and provides results in real time. Both infiltration of fat
and fibrous tissue increase muscle echo intensity; that is,
the muscles become whiter on the ultrasound image [11].
To describe muscle echo intensity, Heckmatt and coworkers
developed a visual grading scale in which grade I represented
normalmuscle (Figure 1) and grade IV represented a severely
increased muscle echo intensity with total loss of bone echo
(we chose biceps versus humerus, Figure 1) [18]. The levels of
brightness of the liver and the biceps were calculated three
times directly from the frozen images.
The common carotid, the carotid bulb, and the near
and far wall segments of the internal carotid were scanned
bilaterally. Subjects were examined in the supine position
with the head turned 45∘ contralateral to the side of scanning.
Images were obtained in longitudinal section, with a single
lateral angle of isonation, optimizing the image for the far
wall. cIMT was defined as the distance between the lumen-
intima and the media-adventitia ultrasound interfaces. Mea-
surements were performed off-line and consisted of six
manual measurements at equal distances along 1 cm on the
far wall of the common carotid. Left and right cIMT were
averaged [19].
2.6. Blood Pressure Measurements. Systolic/diastolic arterial
pressure (SBP, DBP) was the average of three consecutive
readings taken by the physician during the day, during usual
practice hours, after allowing the subjects to rest for five
minutes in the sitting position.
2.7. Laboratory Data. Blood samples were drawn in fasting
individuals. Serum triglycerides (TG), high density lipopro-
tein cholesterol (HDL), basal insulin, alanine aminotrans-
ferase (ALT), pseudocholinesterase (PCH), alkaline phos-
phatase (AP), gamma-glutamyl transpeptidase (gamma-GT),
glycemia, and ferritin were performed by in-house standard
procedures. C-reactive protein (CRP) values were deter-
mined by a high-sensitivity ELISA test, with reference values
between 0.3 and 8.6mg/L in healthy men and between
0.2 and 9.1mg/L in healthy women (BioCheck, Inc., CA,
USA). To have every laboratory test performed, venous blood
samples from the antecubital vein were obtained following
standard procedures. Blood was drawn into a 9mL serum
tube. Samples were centrifuged for 10min at RCF of 850–1000
and freshly analyzed.
A part of sera was collected, aliquoted, and frozen at
−20∘C for the successive determination of SIRT4.
The kit for in vitro quantitative measurement of SIRT4
in human tissue homogenates and other biological fluids,
based on a sandwich enzyme immunoassay, was provided by
Uscn Life Science&TechnologyCompany, 3603Double Lake
Dr., Missouri City, TX 77459. According to manufacturer’s
data, the detection range was 0.156–10 ng/mL. The standard
curve concentrations used for the ELISA were 10 ng/mL,
5 ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL, 0.312 ng/mL,
and 0.156 ng/mL. To verify the reliability of the test, the
generated standard curve was analyzed by linear regression.
The 𝑅2 was 0.9563. The sensitivity of this assay was defined
as the lowest protein concentration that could be differenti-
ated from zero. It was determined by adding two standard
deviations to the mean optical density value of twenty zero
standard replicates and calculating the corresponding con-
centration. The minimum detectable dose of human SIRT4
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was less than 0.051 ng/mL. No significant cross-reactivity or
interference between human SIRT4 and other sirtuins was
observed. Intra-assay precision was determined as follows:
three samples with low, middle, and high level human SIRT4
were tested 20 times on one plate. The interassay precision
was weighed testing three samples with low, middle, and high
level human SIRT4 on 3 different plates, 8 replicates in each
plate. The coefficient of variation, calculated by SD/mean ×
100 for the intra-assay and interassay, was <10% and <12%,
respectively.
The minimum required total sample of population was
calculated using the pooled standard deviation with the level
test 0.05 and power 80% of SIRT4 in obese patients and
controls.
2.8. Liver Histology. The diagnosis of NASH was made when
three out of five criteria were proven by liver biopsy: steatosis,
hepatocyte ballooning, lobular inflammation, portal inflam-
mation, and Mallory bodies. Four criteria, measured by a 3-
point scale, resulting in a sum score ranging from0 to 12, were
adopted. Specifically, the scores were as follows: steatosis: 0 =
none; 1 = up to 33% of acini, mainly macrovesicular; 2 =
34–66% of acini, commonly mixed steatosis; 3 = over 66%
of acini (panacinar), commonly mixed steatosis; hepatocyte
ballooning: 0 = none; 1 = occasional in zone III; 2 =
obvious in zone III; 3 = marked, predominantly in zone III;
lobular inflammation: 0 = none; 1 = scattered neutrophils,
occasional mononuclear cells, 1 or 2 foci per 20x objective;
2 = neutrophils associated with ballooned hepatocytes, mild
chronic inflammation, 3 or 4 foci per 20x objective; 3 = acute
and chronic inflammation, neutrophils possibly concentrated
in zone III, over 4 foci per 20x objective. Portal inflammation
was as follows: 0 = none; 1 = mild, some portal areas; 2 =mild
to moderate, most portal areas; 3 = moderate to severe, most
portal areas. Fibrosis was staged as follows: stage 0 = none;
stage 1 = zone III perivenular, perisinusoidal (pericellular);
stage 2 = stage 1 changes plus periportal fibrosis; stage 3 =
bridging fibrosis; stage 4 = cirrhosis. NASH patients in the
study required a sum score of at least 6 points.
2.9. Statistics. TheNCCLS andClinical and Laboratory Stan-
dards Institute guidelines C28-A2 and C28-A3 for estimating
percentiles and their 90% confidence intervals (99%, double
sided) were followed to calculate the reference limits of SIRT4
with the “robust method.”
Age, SIRT4, GH, TG, ferritin, 𝛾-GT, ALT, CRP, HOMA,
SBP, DBP, W/H ratio, and cIMT were not normally dis-
tributed when analyzed by Shapiro-Wilk (S-W) test, 𝑃 <
0.05, and were expressed as median plus 25–75 interquartile
range (IQR). Data forWC, SAT, VAT, RMR/FFM,HDL, BMI,
fibrinogen, SLD, PCH, and AP, derived from a normally
distributed population (S-W), 𝑃 > 0.05), were articulated
as mean plus SD. The Mann-Whitney (M-W) 𝑈 test for
independent samples was used when managing two popu-
lations to track differences of medians. The means of two
populations were compared by 𝑡-test for independent sample.
Frequencies were evaluated by chi-square. When comparing
the grades of HS or IMTG, the ANOVA Kruskal-Wallis
test, with the Conover-Inman test as post hoc analysis,
was adopted. When the ANOVA analysis was adjusted for
age, considering it as a covariate, the ANCOVA test was
applied. Tracking the degree of association between variables,
Spearman’s rho for nonuniform intervals was used. To assess
the independent effect of a quantitative variable on the
prediction of another one, the linear regression analysis
(least squares) was used, evaluating the coefficient with its
standard error, 95% confidence intervals (CI), the 𝑡 (𝑡-stat),
and 𝑅2. A 𝑡-stat greater than 1.96 with significance less than
0.05 indicates that the independent variable is a significant
predictor of the dependent variable within and beyond the
sample. At multivariate analysis, the multiple regression
(backward stepwise selection) was adopted, firstly entering
all variables if 𝑃 = 0.05 into the model and then removing,
if 𝑃 = 0.1, the nonsignificant variables sequentially, with
a maximum number of 15 steps. The multicollinearity was
set at the variance inflation factor and tolerance values
of >10 and <0.1, respectively. Similarly, to get the sense of
which variables contribute more or less to the regression
equation, the magnitude of standardized coefficient beta (𝛽)
was calculated. The factor analysis was applied to detect
the structure in the relationships among variables, selecting
a subset of variables having the highest correlations with
the principal component factors. The Cattell Scree plot,
with relative eigenvalues, was performed to screen the real
factors. Extraction of the main components amounted to a
variance maximizing (varimax) the rotation of the original
variable space. To evaluate intra-/interobserver variability of
the measurements, the mean difference in the measurements
of the observers was first calculated. Next, the concordance
correlation coefficient (𝜌
𝑐
), which measures precision and
accuracy, was adopted to evaluate the degree of pair observa-
tions at ultrasound, with values >0.8 considered as indicators
of good reliability. MedCalc, version 13 (MedCalc Software,
Broekstraat 52, 9030 Mariakerke, Belgium) and SyStat 13
(Cranes Software International, Bangalore, India) were the
packages used for the statistics.
3. Results
3.1. Prevalence. Anthropometric, clinical, laboratory, ultra-
sound, and calorimetric data are summarized in Table 1.
Serum levels of SIRT4 were measured in 140 obese patients
and in 20 lean subjects without any metabolic alteration. The
minimum required total sample was 106 subjects. The SIRT4
reference interval in healthy subjects was 0–31.8 ng/mL; cir-
culating levels in obese patients were significantly lower than
those present in healthy subjects, that is, 1.2 ng/mL (0.8–1.8)
versus 11 ng/mL (1.2–15),median plus IQR, (M-W)𝑈 test, and
𝑃 = 0.0001, without evident overlapping (Figure 2(a)). Six
out of ten morbidly obese patients who underwent bariatric
surgery patients were diagnosed as having NASH at liver
histology.
Serum levels of SIRT4 were not significantly different
between the three degrees of obesity (ANOVA Kruskal-
Wallis, 𝑃 = 0.9, Figure 2(b)). It should be stressed that the
severely obese patients were largely represented in this study,
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Table 1: Characteristics of the population.
Population (𝑛) Obese patients (140) Healthy subjects (20) Cross-sectional study
Parameter Mean ± SD or median plus(25–75 IQR)
Mean ± SD or median plus
(25–75 IQR) Significance
Age (years) 46 (32–53) 23.5 (19–26) 𝑃 = 0.0001
Gender M/F 62 9 𝑃 = 0.9
Obesity degree I/II/III (𝑛) 20/42/78 0
BMI 42.1 ± 7.4 22.3 ± 1.1 𝑃 = 0.001
WC females cm 117.8 ± 13.2 82.7 ± 3.7 𝑃 = 0.001
WCmales cm 131.6 ± 16 82 ± 2.8 𝑃 = 0.001
W-H ratio females 0.93 ± 0.05 1.17 ± 0.03 𝑃 = 0.001
W-H ratio males 1 ± 0.04 1.17 ± 0.04 𝑃 = 0.001
HS grade 1/2/3 US (𝑛) 32/86/22 0
IMTG score I/II/III/IV US (𝑛) 34/96/4/6 0
SIRT4 ng/mL 1.2 (0.8–1.8) 8 (1.2–15) 𝑃 = 0.0001
HOMA 2.62 (1.53–4.15) 0.43 (0.41–0.48) 𝑃 = 0.0001
Triglycerides mg/dL 128 (93.7–174.5) 103 (98–128) 𝑃 = 0.036
HDL females mg/dL 49.5 ± 12.9 59.5 ± 6.0 𝑃 = 0.025
HDL males mg/dL 40.0 ± 10.1 50 ± 4.3 𝑃 = 0.001
cIMT mm 0.1 (0.07–0.11) 0.06 (0.05-0.06) 𝑃 = 0.001
CRP mg/mL 0.52 (0.30–0.08) 0.12 (0.1–0.18) 𝑃 = 0.001
Fibrinogen g/L 310.7 ± 71.1 267.0 ± 33.7 𝑃 = 0.001
Ferritin females ng/mL 71.1 (21.5–72.29) 68.2 (26–81.3) 𝑃 = 0.4
Ferritin males ng/mL 116 (78–222.5) 108 (58.3–207.4) 𝑃 = 0.046
SLD cm 11.28 ± 1.4 9.8 ± 0.6 𝑃 = 0.001
RMR/FMM 39.5 ± 7.5 42 ± 3.8 𝑃 = 0.035
ALT U/L 27 (21–36.5) 16 (13–20) 𝑃 = 0.0001
Gamma-GT U/L 24 (16–36.2) 15.5 (11–17) 𝑃 = 0.0001
AP 75.9 ± 25.5 97.5 ± 6.7 𝑃 = 0.005
PCH 9375 ± 1793 8781 ± 1210 𝑃 = 0.17
Body mass index (BMI); waist circumference (WC); resting metabolic rate/free fat mass (RMR/FFM); high density lipoprotein cholesterol (HDL); common
carotid intima-media thickness (IMT); waist-to-hip (WH); hepatic steatosis (HS) score; ultrasound (US); spleen longitudinal diameter (SLD), C-reactive
protein (CRP); homeostatic metabolic assessment (HOMA); alanine aminotransferase (ALT); pseudocholinesterase (PCH); alkaline phosphatase (AP);
gamma-glutamyl transpeptidase (gamma-GT).
if compared to those belonging to the groups with mild or
moderate degree of obesity.
When obese subjects were subdivided into three groups
on the basis of fat deposition in the liver (HS), detected at
ultrasound, serum SIRT4 concentrations were significantly
lower in obese subjects with severe grade of HS than in those
with mild grade (ANOVA Kruskal-Wallis test, with post hoc
analysis, 𝑃 = 0.003, Figure 2(c)), not changing when the
values were adjusted for age (ANCOVA, 𝑃 = 0.007).
Obese subjects with severe IMTG, as revealed by ultra-
sound, did not show lower serum SIRT4 levels compared
with milder grades of IMTG (ANOVA Kruskal-Wallis test,
𝑃 = 0.5). Significant differences were found in serum SIRT4
concentrations between severely obese and mildly obese
subjects when the values were adjusted for age (ANCOVA,
𝑃 = 0.01).
3.2. Associations and Predictions. There was no correlation
between serum SIRT4 levels and IR evaluated as HOMA
(𝑃 = 0.1), TG concentrations (𝑃 = 0.4), inflammatory
parameters, that is, SLD (𝑃 = 0.4), fibrinogen (𝑃 = 0.9),
CRP (𝑃 = 0.2), ferritin (𝑃 = 0.1), hemodynamic indices, that
is, SBP (𝑃 = 0.4), DBP (𝑃 = 0.7), and VAT at ultrasound
of females (𝑃 = 0.5), and the calorimetric index, that is,
RMR/FFM (𝑃 = 0.7). The grades of HS at ultrasound and
the scores of steatosis at liver histology were well correlated
(rho = 0.46, 𝑃 = 0.035), and vice versa liver enzymes, that
is, ALT (𝑃 = 0.9), PCH (𝑃 = 0.8), AP (𝑃 = 0.1), and 𝛾-GT
(𝑃 = 0.3), were not associated.
3.3. Univariate Analysis. The prediction of major severity
IMT by lower SIRT4 levels was well documented and clearly
evidenced in Table 2 and Figure 3. The prediction of SLD
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Table 2: Independent variables predicting SIRT4 levels.
Coefficient Std. error 95% CI 𝑡 𝑅2 𝑃
WC
females −0.98 0.34 −1.6 to −0.30 −2.9 0.09 0.0050
WC
males −1.6 0.59 −2.7 to −0.42 −2.7 0.011 0.0086
HDL
females 0.7 0.26 0.23 to 1.25 2.9 0.09 0.0053
HDL
males 1.13 0.28 0.58 to 1.7 4.1 0.21 0.001
HS −0.049 0.013 −0.077 to −0.02 −3.5 0.08 0.0005
Age −0.94 0.23 −1.4 to −0.48 4.0 0.10 0.0001
cIMT −0.0016 0.0006 −0.003 to −0.0004 −2.7 0.05 0.0075
W-H ratio − 0.004 0.0011 0.006 to 0.002 −3.2 0.09 0.003
VAT at US
males −0.19 0.08 −0.36 to −0.03 −2.4 0.08 0.02
HeS −0.026 0.01 −0.048 to −0.004 −2.3 0.04 0.02
BMI −0.49 0.15 −0.80 to −0.19 −3.2 0.07 0.0016
Body mass index (BMI); waist circumference (WC); resting metabolic rate/free fat mass (RMR/FFM); visceral adipose tissue (VAT); high density lipoprotein
cholesterol (HDL); common carotid intima-media thickness (cIMT); waist-to-hip (W-H); hepatic steatosis (HS) score; ultrasound (US); Heckmatt score (Hes).
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Figure 4: Other predictions. Scatter diagram and regression lines. Spleen longitudinal diameter (SLD); waist circumference (WC); resting
metabolic rate/free fat mass (RMR/FFM); visceral adipose tissue (VAT); homeostatic metabolic assessment (HOMA).
Table 3: Rotated loading matrix (varimax, gamma = 1.0) of factor
analysis.
Factor 1 2 3
HOMA 0.827 0.009 −0.275
SLD 0.827 0.009 −0.275
AGE −0.075 0.263 0.776
RMM/FFM −0.024 −0.076 −0.380
SIRT4 0.069 −0.584 −0.166
IMT −0.059 0.292 0.568
VAT 0.609 0.012 0.180
SAT 0.384 −0.529 −0.056
DBP 0.202 −0.048 0.533
SBP 0.134 −0.285 0.562
Ferritin 0.110 0.658 −0.051
fibrinogen 0.349 −0.008 0.026
CRP 0.519 0.046 0.206
PCH −0.115 0.318 0.100
Gamma-GT 0.287 0.301 0.210
ALT 0.313 0.248 −0.231
HDL −0.220 −0.670 0.140
W-H ratio 0.078 0.501 0.168
WC 0.773 −0.017 0.202
BMI 0.685 −0.359 0.242
Percent of total variance explained by factors: 1 (17.8); 2 (11.8); 3 (10.6).
High density lipoprotein cholesterol (HDL); waist circumference (WC);
common carotid intima-media thickness (cIMT); waist-to-hip (W-H);
visceral adipose tissue (VAT); subcutaneous adipose tissue (SAT); systolic
blood pressure (SBP); diastolic blood pressure (DBP); alanine amino-
transferase (ALT); pseudocholinesterase (PCH); C-reactive protein (CRP);
spleen longitudinal diameter (SLD); resting metabolic rate/free fat mass
(RMR/FFM); homeostaticmetabolic assessment (HOMA).The critical value
was calculated by doubling Pearson’s correlation coefficient for a 1% level of
significance (5.152)/square root of the total population (140 + 20) minus 2,
that is, 0.410.
by WC was also demonstrated (𝑡 = 6.7, 𝑅2 = 0.25, and
𝑃 ≤ 0.0001, Figure 4). Equally, VAT was well-predicted
RMR/FFM (𝑡 = 6, 𝑅2 = 0.37, and 𝑃 ≤ 0.0001, Figure 4), and
𝛾-GT was substantially predicted by HOMA (𝑡 = 4.8, 𝑅2 =
0.14, and 𝑃 ≤ 0.0001, Figure 4). The prediction of HS grade
by SLD and RMR/FFMwas particularly evident (𝑡 = 6.4,𝑅2 =
0.22, and 𝑃 ≤ 0.0001 and 𝑡 = −2.18, 𝑅2 = 0.07, and 𝑃 = 0.03,
resp.).
Other significant predictions of independent variables
on circulating levels of SIRT4 were HDL of males and age,
among the most significant ones, with an 𝑅2 of 0.21 and
0.10, respectively. About age, also factor analysis confirmed
its main role as risk factor for CAD (see below).
3.4. Multivariate Analysis. Among the classical cardiovascu-
lar risk factors such as age, hypertension, cIMT, IR, dyslipi-
demia, HS, and visceral obesity, at the multiple regression
equation, only HDL (𝛽 = 0.285. 𝑃 = 0.001) and age (𝛽 =
−0.18, 𝑃 = 0.038) were included in the model as independent
predictors of SIRT4 levels, with IMT being not present due to
the multicollinearity between it and the former ones.
3.5. Factor Analysis. According to Table 3, it revealed, as
hidden relationships, that HOMA was strongly related to
adiposity grade, that is, BMI, WC, VAT, and with markers
of low-grade chronic inflammation, that is, CRP and SLD.
Ferritin stood with WH ratio alone, not linked to other
inflammatory markers. The latter parameters showed no
correlation with the common carotid IMT increase. Finally,
age, cIMT, SAP, andDAP shared the samebehavior.The intra-
/interobservational variability of the ultrasound estimations
was not significant, with mean difference = 1.7, 2.2, 2.5, 2.3,
and 1.9%, and 2.1, 3.3, 3.9, 4.6, and 3. 1% for the HS, VAT, SAT,
SLD, and common carotid IMT, respectively, with a 𝜌
𝑐
of 0.92.
4. Discussion
The novel finding of this study was that lower serum levels
of SIRT4 were present in obese subjects with HS and IMTG,
independent of the severity of obesity. SIRT4 levels showed a
strict relationship to some parameters reckoned as CAD risk
factors, that is, low HDL, visceral obesity expressed as high
W/Hratio but also as abundantVAT, evaluated by ultrasound,
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and finally increased cIMT. Of interest, the lowest SIRT4
levels were found in older obese males.
Trying to explain the finding that serum SIRT4 concen-
trations were significantly lower in obese subjects with severe
grade ofHS than in thosewithmild grade,we should take into
account the following research data: (i) the increased degree
of oxidative stress, due to decreased mitochondrial oxidative
phosphorylation, initiating lipid deposition in the liver [20],
(ii) the mitochondrial dysfunction, inducing apoptosis [21],
mitochondrial permeability transition [22], and endoplasmic
reticulum (ER) stress [23], (iii) the adjunct role of FFAs in
inducing ER stress, leading to the progression of NAFLD
[24], and (iv) the presence of reactive oxygen species (ROS)
causing in turn the mitochondrial permeability transition
pore to open [25]. ROS increase the inflammatorymilieu that
induces/worsens IR [26], a key mechanism of NAFLD. Since
mitochondrial dysfunction in obese patients is not only the
basis of NAFLD, but also of IMTG storage in skeletalmuscles,
increased blood concentrations of SIRT4 as a consequence
of a sort of leakage of SIRT4 from mitochondria would be
expected for detection. In contrast, our data did not confirm
this expectation, although it is in line with the low SIRT4
expression in peripheral blood leukocytes of patients with
type 2 diabetes mellitus [6].
We hypothesize that SIRT4 expression is likely dimin-
ished in the mitochondria in response to a high calorie diet
and lack of exercise and is an attempt to decrease fat oxidative
capacity reducing the mitochondrial ROS production in the
liver and in muscle, but promoting the ectopic lipid storage,
according to the hypothesis that mitochondrial functions
are adjusted to meet environmental demands and maintain
energy homeostasis [27].
The present study provided evidence that older male
obese patients, characterized by the lowest serum SIRT4
combined with severe grade of HS and IMTG, were at greater
risk than those with moderately low or normal SIRT4 levels.
In other words, obese individuals withmoderately low SIRT4
levels, due to disturbed muscle fat 𝛽-oxidation—a primary
event in the etiology of obesity—were still able to provide
a sufficient 𝛽-oxidation of FFAs that leads to less organ fat
storage without forming excess ROS. In this context, the
lack of associations between SIRT4 and HOMA as well as
between markers of low-grade chronic inflammation and
RMR/FFM—clue of reduced energy expenditure and oxygen
consumption—lends credence to this hypothesis.
What was the link between SIRT4 and CAD risk? The
obese phenotype, associated with great concentrations of
FFAs released by adipose tissue, conveys endothelial dysfunc-
tion via oxidative stress [28], increased vascular endothelial
factors, and nitric oxide imbalance. Visceral fat due to its
close associationwith portal circulation has an additional role
in endothelial dysfunction through hepatic IR. A collateral
finding of this study was that visceral fat accumulation is
associated with RMR [29] and is a significant predictor of
HS, which in turn is related to CAD via low-grade chronic
inflammation [19].
4.1. Limitations. A comparative tissue evaluation of SIRT4
expression or activity in hepatocyte or myocyte cultures
was lacking. Equally, it would surely be of interest to have
hepatic histology in every obese patient, but the lack of
significant increase of liver enzymes avoided performing liver
biopsy. Adiposity was not evaluated by themore preciseMRI.
Arterial stiffness could have represented a more valid choice
to test the early atherosclerosis presence. Another limitation
was the lack of clamp method that could have better clarified
the association between serum SIRT4 levels and IR. Finally,
it was evaluated neither the contextual variation of other
sirtuins coordinating the oxidative capacity of tissue nor the
presence of cross-reactivity with other sirtuins.
5. Conclusions
The finding of low circulating levels of SIRT4 deserves to be
confirmed by other laboratory methods and by studies on
larger populations, possibly including obese patients followed
up for long periods.
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